Shoujun Li, MD

CONTACT

Lead Sponsor

China National Center for Cardiovascular Diseases

Age

0 - 18 years

Sex

ALL

Healthy Volunteers

No

•1. 6 months \< age ≤ 18 years;
•2. ESC 2022 Group I PAH;
•3. Have received standardized drug therapy for at least 6-9 months and still remain at intermediate to high/high-risk status of the criteria of ESC2022;
•4. Presenting with significant clinical manifestations (i.e., progressive symptoms/syncope history/growth and development restriction, etc);
•5. Informed consent form signed by the patient and their guardian.

•1. ESC 2022 Group II-V PAH;
•2. Poor right ventricular function: RVEF \< 25% or RVFAC \< 20%;
•3. Deteriorated general condition: requiring ICU resuscitation or ECMO assistance;
•4. Pulmonary artery pressure/main arterial pressure ratio \< 0.7;
•5. Six-minute walk distance \< 150 meters (only applicable to patients aged 8 and above);
•6. No significant improvement in RVEF under triple drug therapy.